Table 4.
Initial biochemical data of among MMA mutase, MMA cblB, PA and false positive patients upon their admission
| False positive (n = 10) | MMA | PA (n = 4) | ||
|---|---|---|---|---|
| mut (n = 18) | cbl (n = 1) | |||
| ALT(IU) (0–40) | 15.00 ± 4.83 (6–21) | 43.64 ± 48.34* (11-166) | 14 | 18.00 ± 9.83a (6–30) |
| AST(IU) (5–45) | 30.5 ± 21.89 (19–92) | 98.64 ± 115.96* (19-451) | 34 | 44.50 ± 20.94a (21–69) |
| Bun(mg/dl) (7–20) | 10.67 ± 4.37 (6–18) | 13.18 ± 8.88 (2–35) | 8 | 13.08 ± 10.65 (7–29) |
| Cre(mg/dl) (0.5–1.5) | 0.23 ± 0.14 (0.1–0.39) | 0.62 ± 0.47* (0.1-2.0) | 0.42 | 0.50 ± 0.16* (0.3-0.69) |
| NH3(μg/dl) (5–150, newborn) | 70.58 ± 27.25 (35.8–132) | 388.89 ± 299.07* (92-1244) | 253 | 341.00 ± 227.28* (84-637) |
| pH value (7.40 ± 0.08) | 7.43 ± 0.08 (7.305–7.54) | 7.28 ± 0.14* (6.94-7.47) | 7.55 | 7.37 ± 0.11 (7.229–7.476) |
| HCO3 (20 ± 4) | 20.54 ± 3.19 (14.5–26.3) | 13.97 ± 6.38 (2.0–25.3) | 8.7 | 18.10 ± 4.07 (13.5–22) |
| Glycine (μM) (110–240) | 227.7 ± 52.61 (190.5–264.9) | 533.49 ± 221.21* (238-1163.5) | 148.9 | 592 ± 106.06 (84–667) |
*indicated significant difference (p < 0.05) compared to false positive group
aindicated significant difference compared to mutase type patients